Two balance-sheet ratios against market capitalisation and a test on the line of business, run across every listed US company over a billion dollars. Screened on AAOIFI’s limits, which are the strictest of the five published sets — a company clearing them clears the other four on these ratios as well.
Enter an ETF and every holding is put through the same screen as a company’s report. The result is the share of the fund’s money that passes, fails, or could not be screened — and how much each of the five standards would exclude on its own.
Needs live data. Fund holdings are read live; without a connection there is nothing to screen.
Invesco Biotechnology & Genome ETF (PBE) is not a Shariah-compliant fund: 18.2% of its weight is in companies that fail the Shariah screen, through their line of business or their debt and cash. 78.6% passes and 3.3% could not be screened.
| Holding | Weight | Why |
|---|---|---|
| COLL Collegium Pharmaceutical Inc | 2.6% | Debt 136.8% of market cap |
| BMRN BioMarin Pharmaceutical Inc | 2.5% | Debt 37.1% of market cap |
| NVAX Novavax Inc | 2.4% | Cash and short-term investments 47.4% of market cap |
| PTCT PTC Therapeutics Inc | 2.3% | Cash and short-term investments 42.2% of market cap |
| ARDX Ardelyx Inc | 2.3% | Debt 32.0% of market cap; Cash and short-term investments 35.9% of market cap |
| SRPT Sarepta Therapeutics Inc | 2.2% | Debt 54.2% of market cap; Cash and short-term investments 56.2% of market cap |
| BCRX |
Invesco Biotechnology & Genome ETF (PBE) is not a Shariah-compliant fund: 18.2% of its weight is in companies that fail the Shariah screen, through their line of business or their debt and cash. 78.6% passes and 3.3% could not be screened.
78.6% of the fund's weight (21 of 33 holdings) is in companies that pass; 18.2% (8 holdings) fails; 3.3% (4 lines) could not be screened.
The largest are COLL (2.6%), BMRN (2.5%), NVAX (2.4%), PTCT (2.3%), ARDX (2.3%), SRPT (2.2%), BCRX (2.1%), ACAD (1.7%). Banks, insurers, credit and asset managers, alcohol, tobacco and gambling are excluded on their business; the others carry debt or cash above 30% of their market value.
Funds with a Shariah mandate screen their holdings and purify their income: SPUS, HLAL, UMMA, SPTE, SPWO. Each has its own page here, with the same holding-by-holding check.
Each holding goes through the halal stock screener's test: interest-bearing debt and cash plus short-term investments each under 30% of market cap (AAOIFI's limits, the strictest of the five published sets), and a line of business that is not excluded. Holdings are as the fund reported them on November 17, 2026; companies listed outside the US, cash, bonds and derivatives are not screened.
Shariah funds checked the same way: Is SPUS halal?, Is HLAL halal?, Is UMMA halal?, Is SPTE halal?, Is SPWO halal?. All halal ETFs compared. Run all five published standards on this fund with the check below.
A mechanical screen of published financial ratios and each company's line of business, not a religious ruling. It does not test income from excluded activities; check with a scholar you trust.
| 2.1% |
| Debt 42.6% of market cap |
| ACAD ACADIA Pharmaceuticals Inc | 1.7% | Cash and short-term investments 30.9% of market cap |